Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2005-12-19
2009-11-03
Goddard, Laura B (Department: 1642)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007230
Reexamination Certificate
active
07611845
ABSTRACT:
The present invention relates to methods of diagnosing prostate cancer, predicting disease progression of prostate cancer, prognosing the stage and state of prostate cancer, and identifying appropriate treatment indication for prostate cancer patients. Methods encompass determining the levels of HER-2
eu in fluid biological samples (e.g., blood and serum) from patients.
REFERENCES:
Tockman et al (Cancer Res., 1992, 52:2711s-2718s).
Slamon et al. (Science vol. 235, Jan. 1987, pp. 177-182).
Arai et al (The Prostate, 1997, 30:195-201, IDS).
Shin et al (Proceedings of ASCO, 2002, 21:429a, Abstract# 1713, IDS).
Myers et al (Int j Cancer (Pred Oncol), 1996, 69:398-402).
Shin et al (Proceedings of ASCO, 2002, 21:429a, Abstract# 1713, IDS).
Stein and Staros, BMC Evolutionary Biology, 2006, 6:79, p. 1-17.
Kanamaru et al (Japanese Journal of Clinical Oncology, Mar. 1999, 29:151, internet pp. 1-9 and Figures 1, 2a, and 2b).
Osman, I., et al., HER-2
eu (p185neu) protein expression in the natural or treated history of prostate cancer. Clin Cancer Res, 2001. 7(9): p. 2643-7.
Fossa, A., et al., Independent prognostic significance of HER-2 oncoprotein expression in pN0 prostate cancer undergoing curative radiotherapy. Int J Cancer, 2002. 99(1): p. 100-5.
Shi, Y., et al., Her-2
eu expression in prostate cancer: high level of expression associated with exposure to hormone therapy and androgen independent disease. J Urol, 2001. 166(4): p. 1514-9.
Signoretti, S., et al., Her-2-neu expression and progression toward androgen independence in human prostate cancer. J Natl Cancer Inst, 2000. 92(23): p. 1918-25.
Lara, P.N., Jr., et al., Trastuzumab plus docetaxel in HER-2
eu-positive prostate carcinoma: final results from the California Cancer Consortium Screening and Phase II Trial. Cancer, 2004. 100(10): p. 2125-31.
Scher, H.I. and G. Heller, Clinical states in prostate cancer: toward a dynamic model of disease progression. Urology, 2000. 55(3): p. 323-7.
Scher, H.I., et al., Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol, 2004. 22(3): p. 537-56.
Nunes, R.A. and L.N. Harris, The HER2 extracellular domain as a prognostic and predictive factor in breast cancer. Clin Breast Cancer, 2002. 3(2): p. 125-35; discussion 136.7.
Arai, Y., T. Yoshiki, and O. Yoshida, c-erbB-2 oncoprotein: a potential biomarker of advanced prostate cancer. Prostate, 1997. 30(3): p. 195-201.
Shin, B.Y, et al, Elevated serum HER-2
eu in metastatic prostate cancer. Meeting Proceedings of the American Society of Clinical Oncology, 2002. Abstract 1713. Abstract presented at the 2002 ASCO Annual Meeting.
Ross, J.S., et al., Mol Cell Proteomics, 2004. 3.4: p. 379-398.
Morris, M.J., et al., Cancer, 2002. 94:2: p. 980-986.
Payne, R.C., et al., Clinical Chemistry, 2000, 46:2: p. 175-182.
Osman, I., et al., Serum levels of shed HER-2
eu protein in men with prostate cancer correlate with disease progression. Journal of Urology, 2005, vol. 174. p. 2174-2177.
Scher et al., “Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer,”Endocrine-Related Cancer, 11: 459-476 (2004).
Coussens et al., “Tyrosine Kinase Receptor with Extensive Homology to EGF Receptor Shares Chromosomal Location withneuOncogene,”Science, 230: 1132-1139 (1985).
Cheli Carol D.
Taneja Samir
Goddard Laura B
Siemens Healthcare Diagnostics Inc.
Stein, Esq Kevin
LandOfFree
Serum levels of HER2/neu as an indicator of clinical state... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Serum levels of HER2/neu as an indicator of clinical state..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Serum levels of HER2/neu as an indicator of clinical state... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4065243